Completed OBSERVATIONAL NCT01552174

Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice (MEIBUM)

Sponsor: Axial Biotech, Inc

Conditions Meibomian Gland Dysfunction Ocular Surface Disease Palpebral Pathologies

Updated 6 times since 2017 Last updated: Aug 31, 2015 Started: Mar 31, 2012 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Meibomian Gland Dysfunction and Ocular Surface Disease, this trial is completed. The trial is conducted by Axial Biotech, Inc and has accumulated 6 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Axial Biotech, Inc
Iris Pharma
Laboratoires Thea

Data source: Laboratoires Thea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heidelberg, Germany
• Madrid, Spain